Charles River (CRL) CEO Birgit Girshick Exercises Options, Sells 6,500

What Happened

• Birgit Girshick, CEO of Charles River Laboratories (CRL), exercised options to acquire 6,500 shares on 2026-08-11 (exercise price $179.66/share, cost $1,167,790) and immediately sold those 6,500 shares in an open-market sale at $279.90/share for $1,819,350. Net proceeds before taxes and fees were about $651,560. The filing also shows the related derivative position was disposed (cancelled) upon exercise.

Key Details

• Transaction date: 2026-08-11 (reported on Form 4 filed 2026-08-13)
• Exercise: 6,500 shares acquired at $179.66 each — total cost $1,167,790
• Sale: 6,500 shares sold at $279.90 each — gross proceeds $1,819,350
• Net difference (sale proceeds minus exercise cost): ~$651,560 (before taxes/fees)
• Derivative disposition: 6,500-option position reported disposed at $0 (reflects conversion/cancellation on exercise)
• Shares owned after transaction: not specified in the provided filing
• Footnote: Transaction was executed pursuant to a Rule 10b5‑1 trading plan adopted March 3, 2025
• Timeliness: Filing appears timely (transaction 8/11/2026; Form 4 filed 8/13/2026)

Context

• This was an option exercise followed by an immediate sale (a cashless-style transaction), which is commonly used by insiders to realize gains and does not necessarily signal a change in sentiment. The use of a pre-established 10b5‑1 plan means the trade was executed under a previously arranged schedule.